| |
|
Headlines:
|
 |
Back to index
CMF oral regimen
| |
Breast Cancer News |
| |
 |
| |
|
| |
|
| |
|
| |
Breast Cancer |
| |
|
| |
|
|
Abstract: Combination chemotherapy as an adjuvant treatment in operable
breast cancer.
Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate
and fluorouracil was evaluated as adjuvant treatment to radical mastectomy
in primary breast cancer with positive axillary lymph nodes. After 27 months
of study, treatment occurred in 24 per cent of
179 control patients and in 5.3 per cent of
207 women given combination chemotherapy
(P less than 10(-6)), the advantage appearing statistically significant
in all subgroups of patients. Patients with four or more positive axillary
nodes had a higher per cent of relapses than those with fewer nodes. The
initial new clinical manifestations occurred in distant sites in 81.5 per
cent of relapsed patients. Long-term chemotherapy produced an acceptable
toxicity, thus allowing the administration of a high percentage of drug
dosage. These results should be considered with caution, since, at present,
the effect of this therapy on survival and possible long-term side effects
remain unknown.
References
Bonadonna G. Brusamolino E. Valagussa P. Rossi A. Brugnatelli
L. Brambilla C. De Lena M. Tancini G. Bajetta E.
Musumeci R. Veronesi U. Combination chemotherapy as an adjuvant treatment
in operable breast cancer. New England Journal of Medicine. 294(8):405-10,
1976 Feb 19.
Editors Note:
This study was reported in 1976 and is regarded as a landmark study
because it was one of the earliest studies to show the efficacy of
combination chemotherapy and also because it was one of the earliest
justifications for the use of adjuvant chemotherapy.

|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
Cytoxan......... 100 mg/sqm
orally days 1 to 14.
Methotrexate.... 40 mg/sqm IV days 1 and 8.
Fluorouracil.... 600 mg/sqm IV days 1 and 8.
FREQUENCY....... Repeat cycle every 28 days. |
|
|
| |
|
|
| |
Summary |
Adjuvant
CMF vs. control group (no chemotherapy) |
| |
Disease progression |
5.3% vs. 24% in the control group |
| |
|
|
|
|